Ronald van der Rol

Define and execute the EU+ commercial strategies for its current MS portfolio & future products. EU+ Commercial Lead for Biogens’ activities in the development of SMNRx; a potential treatment for SMA (Spinal Muscular Atrophy). Lead the commercial activities for Biogen at International Congresses, like EAN, ECTRIMS, EFNS and WCN. Booth development, content creation and the actual delivery of the activities on site.

Commercial lead for the launch of a treatment for ALS (Amyotrophic lateral sclerosis). Leading the x-functional preparation for the launch of TECFIDERA (Multiple Sclerosis). Overall accountable for Biogen’s presence at international congresses; developed content for MS Summit Meetings (1-2 day customer medical education), led the faculty and maintained contact. Manage a team of people (Meeting Management Services) that organize and execute all internal and external meetings and congresses.

EU+ Commercial Lead for the launch of ‘FAMPYRA’, a symptomatic treatment for people with MS Multiple Sclerosis). Led the Regional go-to-market preparations in terms of marketing, sales and managed the Joint Collaboration Committee with the partner company Acorda (which was responsible for US).

Build-out a stand alone country organization for Belgium & Luxemburg; from 6 people in 2007 to 18 people at the end of 2009. Successfully launched TYSABRI (MS treatment) in 2007.

Core competencies developed: Organizational restructuring and continued development, Hands-on sales management, Customer interactions on country level, product launch and maintaining current business as part of the BeNeLux management Team.

Internet startup company funded by Johnson&Johnson and Nokia for the improvement of the quality of life for people with diabetes.

Marketing, Marketing Management & Key Account Management